ECSP18087725A - 3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas - Google Patents

3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas

Info

Publication number
ECSP18087725A
ECSP18087725A ECSENADI201887725A ECDI201887725A ECSP18087725A EC SP18087725 A ECSP18087725 A EC SP18087725A EC SENADI201887725 A ECSENADI201887725 A EC SENADI201887725A EC DI201887725 A ECDI201887725 A EC DI201887725A EC SP18087725 A ECSP18087725 A EC SP18087725A
Authority
EC
Ecuador
Prior art keywords
compounds
diphenyl
oxo
preparing
pharmaceutical compositions
Prior art date
Application number
ECSENADI201887725A
Other languages
English (en)
Inventor
Lars Roese
Ilona Gutcher
Ulrike Roehn
Michael Platten
Benjamin Bader
Norbert Schmees
Detlef Stoeckigt
Na Zhao
Horst Irlbacher
Ludwig Zorn
Original Assignee
Deutsches Krebsforschungszentrum Dkfz
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforschungszentrum Dkfz, Bayer Pharma AG filed Critical Deutsches Krebsforschungszentrum Dkfz
Publication of ECSP18087725A publication Critical patent/ECSP18087725A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C07D237/16—Two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención cubre compuestos de 3–oxo–2,6–difenil–2,3–dihidropiridazin–4–carboxamida de fórmula general (I): en la cual R1, R2, R3, R4, R5 y R6 son según lo definido en la presente invención, métodos para preparar dichos compuestos, compuestos intermedios útiles para preparar dichos compuestos, composiciones y combinaciones farmacéuticas que comprenden dichos compuestos y la utilización de dichos compuestos para manufacturar composiciones farmacéuticas para el tratamiento o profilaxis de enfermedades, en particular del cáncer o afecciones con respuestas inmunes desreguladas u otros trastornos asociados con la señalización aberrante del AHR, como un agente único o en combinación con otros ingredientes activos.
ECSENADI201887725A 2016-05-25 2018-11-23 3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas ECSP18087725A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2016083308 2016-05-25
CN2017074408 2017-02-22

Publications (1)

Publication Number Publication Date
ECSP18087725A true ECSP18087725A (es) 2018-11-30

Family

ID=58745251

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201887725A ECSP18087725A (es) 2016-05-25 2018-11-23 3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas

Country Status (27)

Country Link
US (1) US11040035B2 (es)
EP (1) EP3464248B1 (es)
JP (1) JP6964096B2 (es)
KR (1) KR20190009369A (es)
CN (1) CN109863140B (es)
AU (1) AU2017269870A1 (es)
BR (1) BR112018074185A2 (es)
CA (1) CA3025227A1 (es)
CL (1) CL2018003345A1 (es)
CO (1) CO2018012654A2 (es)
CR (1) CR20180556A (es)
CU (1) CU20180143A7 (es)
DO (1) DOP2018000256A (es)
EA (1) EA201892666A1 (es)
EC (1) ECSP18087725A (es)
IL (1) IL263046A (es)
MA (1) MA45087A (es)
MX (1) MX2018014443A (es)
NI (1) NI201800124A (es)
PE (1) PE20190509A1 (es)
PH (1) PH12018502472A1 (es)
SG (1) SG11201810366WA (es)
SV (1) SV2018005787A (es)
TN (1) TN2018000392A1 (es)
TW (1) TW201742859A (es)
UY (1) UY37256A (es)
WO (1) WO2017202816A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI759301B (zh) 2016-05-24 2022-04-01 美商安美基公司 聚乙二醇化卡非佐米化合物
JOP20190193A1 (ar) 2017-02-09 2019-08-08 Bayer Pharma AG ممركبات 2-أريل غير متجانس-3-أكسو-2، 3-ثنائي هيدرو بيريدازين-4-كربوكساميد لمعالجة السرطان
PT3580211T (pt) * 2017-11-21 2021-02-01 Deutsches Krebsforsch 2-heteroaril-3-oxo-2,3-di-hidropiridazina-4-carboxamidas para o tratamento de cancro
CA3082856A1 (en) 2017-11-21 2019-05-31 Bayer Aktiengesellschaft Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides
WO2019101643A1 (en) * 2017-11-21 2019-05-31 Bayer Aktiengesellschaft 3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyridazine-4-carboxamides
WO2019101647A1 (en) * 2017-11-21 2019-05-31 Bayer Aktiengesellschaft 2-phenylpyrimidine-4-carboxamides as ahr inhibitors
CN112739698A (zh) 2018-08-24 2021-04-30 捷豹治疗有限公司 作为ahr调节剂的四氢嘧啶衍生物
US20210395242A1 (en) 2018-08-31 2021-12-23 Jaguahr Therapeutics Pte Ltd Heterocyclic compounds as ahr modulators
CN109771437B (zh) * 2019-03-28 2023-03-17 西安交通大学医学院第一附属医院 三氟胸苷在制备治疗三阴性乳腺癌药物中的应用
EP3715471A1 (en) * 2019-03-29 2020-09-30 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Ahr signature marker set
EP3721894A1 (en) 2019-04-10 2020-10-14 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Interleukin-4-induced gene 1 (il4i1) as a biomarker and uses thereof
JPWO2021020362A1 (es) * 2019-07-29 2021-02-04
EP3835432A1 (en) 2019-12-10 2021-06-16 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Interleukin-4-induced gene 1 (il4i1) and respective metabolites as biomarkers for cancer
AU2020403801A1 (en) * 2019-12-16 2022-06-02 Bayer Aktiengesellschaft Combination of an AhR-inhibitor and an PD1-inhibitor antibody and its use in the treatment of cancer
MX2022008532A (es) 2020-01-10 2022-09-09 Ikena Oncology Inc Inhibidores de hidrocarburo de arilo (ahr) y usos de estos.
CN115244048A (zh) 2020-02-26 2022-10-25 捷豹治疗有限公司 可用于调节AhR信号传导的吡啶并嘧啶衍生物
MX2022011826A (es) * 2020-03-27 2022-10-18 Dong A St Co Ltd Derivados de aminopirimidina y su uso como moduladores del receptor de hidrocarburos de arilo.
US11911376B2 (en) 2020-03-30 2024-02-27 The Regents Of The University Of Colorado Methods for preventing and treating retinal damage
CN114181212B (zh) * 2020-09-15 2023-06-06 山东轩竹医药科技有限公司 哒嗪酮类AhR抑制剂
WO2022078356A1 (zh) * 2020-10-15 2022-04-21 山东轩竹医药科技有限公司 杂芳环类AhR抑制剂
CN114685426A (zh) * 2020-12-28 2022-07-01 苏州泽璟生物制药股份有限公司 磺酰胺类抑制剂及其制备方法和应用
WO2023043753A1 (en) * 2021-09-14 2023-03-23 Allianthera (Suzhou) Biopharmaceutical Co., Ltd. 2-aryl or heteroaryl-3-oxo-4-carbamide-6-cyclic-dihydropyrazine aryl hydrocarbon receptor modulators and their use in the treatment of diseases and disorders
WO2024076300A1 (en) 2022-10-03 2024-04-11 Jaguahr Therapeutics Pte Ltd Compounds useful in modulation of ahr signalling

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4134467A1 (de) * 1991-10-18 1993-04-22 Thomae Gmbh Dr K Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
WO2000009488A1 (fr) 1998-08-14 2000-02-24 Nihon Nohyaku Co., Ltd. Derives de pyridazinone
KR100770327B1 (ko) 2000-09-18 2007-10-25 에자이 알앤드디 매니지먼트 가부시키가이샤 피리다지논 및 트리아지논 화합물류 및 그들의 의약 용도
FR2847253B1 (fr) * 2002-11-19 2007-05-18 Aventis Pharma Sa Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant
FR2847235B1 (fr) 2002-11-20 2005-07-08 Essilor Int Emballage de protection et de calage pour objets a contour circulaire
AR057986A1 (es) * 2005-11-21 2008-01-09 Japan Tobacco Inc Compuesto heterociclico y su uso farmaceutico
EP2328586A2 (en) 2008-05-20 2011-06-08 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
CN107648216B (zh) 2010-07-27 2021-03-30 波士顿大学管理委员会 作为新型癌症疗法的芳烃受体(AhR)调节剂
WO2015143164A1 (en) 2014-03-19 2015-09-24 President And Fellows Of Harvard College Antimicrobial agents and screening methods

Also Published As

Publication number Publication date
KR20190009369A (ko) 2019-01-28
EP3464248B1 (en) 2021-09-08
CR20180556A (es) 2019-04-23
CA3025227A1 (en) 2017-11-30
PE20190509A1 (es) 2019-04-10
CN109863140B (zh) 2023-02-21
EP3464248A1 (en) 2019-04-10
US11040035B2 (en) 2021-06-22
TW201742859A (zh) 2017-12-16
JP2019516744A (ja) 2019-06-20
WO2017202816A1 (en) 2017-11-30
EA201892666A1 (ru) 2019-08-30
SG11201810366WA (en) 2018-12-28
CN109863140A (zh) 2019-06-07
CO2018012654A2 (es) 2018-12-14
CU20180143A7 (es) 2019-07-04
SV2018005787A (es) 2019-02-07
BR112018074185A2 (pt) 2019-03-06
MA45087A (fr) 2021-05-26
UY37256A (es) 2018-01-02
TN2018000392A1 (en) 2020-06-15
NI201800124A (es) 2019-04-29
MX2018014443A (es) 2019-04-15
PH12018502472A1 (en) 2019-09-23
DOP2018000256A (es) 2019-02-15
US20200237757A1 (en) 2020-07-30
IL263046A (en) 2018-12-31
AU2017269870A1 (en) 2018-12-06
JP6964096B2 (ja) 2021-11-10
CL2018003345A1 (es) 2019-03-15

Similar Documents

Publication Publication Date Title
ECSP18087725A (es) 3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas
ECSP19057713A (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas para el tratamiento del cáncer
DOP2019000110A (es) 1,2,4–triazolonas 2,4,5–trisustituidas
UY37460A (es) 1,2,4-triazolonas con anelación en 4 y 5
DOP2019000117A (es) Nuevos derivados de quinolina
CO2020001244A2 (es) Derivados de quinolina para tratar infecciones con helmintos
PH12016501807A1 (en) Novel compounds
UY37971A (es) Derivados de indol macrocíclicos sustituidos
PH12017501133A1 (en) Pyrazolopyridinamines
UY37973A (es) Derivados de indol macrocíclicos
MX2022001803A (es) [1,2,4]triazolo[1,5-c]quinazolin-5-aminas.
PH12016501814A1 (en) Inhibitors of the wnt signalling pathways
CL2019001004A1 (es) Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y usos de los mismos.
BR112017003227A2 (pt) composto, composição farmacêutica e uso de um composto
UY35600A (es) "composiciones farmacéuticas que comprenden compuestos derivados de triazolopiridina y métodos para prepararlas"
EA201991835A1 (ru) 2-гетероарил-3-оксо-2,3-дигидропиридазин-4-карбоксамиды для лечения злокачественного новообразования
UY37032A (es) Compuestos de heteroarilbenzimidazol
MA39762A (fr) Nouveaux composés